Related Experiment Video

Updated: Jun 14, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

Are we ready for an MRD-driven approach in multiple myeloma?

Francesca Gay1, Roberto Mina1

  • 1University of Turin.

Blood
|July 3, 2025
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.6K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K

Related Experiment Videos

Last Updated: Jun 14, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.6K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma.

Cells·2026

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Nature medicine·2026

Genetic Evidence against Clonotypic B Lymphocytes as a Reservoir for Plasma-cell Cancers.

Blood cancer discovery·2026

Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168.

Cancers·2025

The Emerging Role of Left Atrial Strain in Cardiovascular Risk Stratification for Multiple Myeloma Patients Undergoing Carfilzomib Therapy.

Cancers·2025

Measurable Residual Disease-Dependent Unfavorable Outcomes in Pediatric PAX5-Rearranged B-Acute Lymphoblastic Leukemia.

Blood·2026

The hepatic FGFR-ERK-HRG axis regulates heparin-induced thrombocytopenia with thrombosis.

Blood·2026

HOW I TREAT BLEEDING IN WOMEN AND GIRLS WITH HEMOPHILIA/ HEMOPHILIA CARRIERS.

Blood·2026

FERMT3 alternative splicing enhances kindlin-3 membrane recruitment for neutrophil adhesion during stress myelopoiesis.

Blood·2026

Risk of recurrence in patients with provoked venous thromboembolism: a prospective cohort study.

Blood·2026

How I treat autoimmune neutropenia in adults.

Blood·2026

Native Label-Free Spectral Biochemical Fingerprinting of an Enveloped Mammalian RNA Virus Reveals Mode of Action of a Virucidal Drug.

Small methods·2026

Continuous double-layer suturing technique for uniportal thoracoscopic diaphragmatic plication after phrenic nerve resection of thymoma: a technical case report.

International journal of surgery case reports·2026

Hepatotropic Nanomedicine and Targeted Nanocarriers for Liver Diseases and Hepatocellular Carcinoma.

International journal of nanomedicine·2026

Myocarditis in the Modern Era: Navigating Diagnosis, Innovative Treatments, the COVID-19 Challenge and the Role of Artificial Intelligence.

Cardiology research and practice·2026

Bionic intelligent responsive barbed microneedles synergistically remodel the microenvironment for the treatment of refractory pigmentation disorders (melasma).

Materials today. Bio·2026

Unveiling the contribution of histidine-end-terminal pBAEs to endosomal escape using super-resCLEM imaging.

Materials today. Bio·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us